Floatz logo

FALLYPRIDE

Hematologic Malignancies

National Cancer Institute (NCI)Small moleculePhase 1/2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

50 Active assets in the Hematologic Malignancies cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 2BB
cc-5013
CellCentric Ltd.
Phase 4BB
Evomela
Thomas Jefferson University
Phase 2BB
TACROLIMUS
National Cancer Institute (NCI)
Phase 2BB
Monomethyl Fumarate
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

FALLYPRIDE is also rated in:

Alzheimer DementiaDormant
BB
Indicative ·
67 / 100
View asset →
Essential TremorDormant
BB
Indicative ·
64 / 100
View asset →
Breast CancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →